Cabozantinib

About Exelixis

Exelixis has evolved into a multi-platform cancer company over three decades, transitioning from early-stage development to commercial success with approved oncology treatments. The company operates through both small molecule discovery and biotherapeutics platforms, with a robust pipeline including next-generation TKIs and innovative biologics. Their strategic approach combines internal R&D capabilities with external partnerships to advance multiple clinical programs across various cancer types.

Therapeutic Areas

Other Advanced Renal Cell Carcinoma Drugs